Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

Stephen E. Jones; Gary Clark; Sherry Koleszar; Gaby Ethington; Robert Mennel; Steven Paulson; Barry Brooks; Ronald Kerr; Claude Denham; Michael Savin; Joanne Blum; Robert Kirby; Marvin Stone; John Pippen; Timothy George; Douglas Orr; Sally Knox; Michael Grant; George Peters; Daniel Savino; Charles Rietz

doi:10.3816/CBC.2002.n.019

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

Stephen E. Jones, Gary Clark, Sherry Koleszar, Gaby Ethington, Robert Mennel, Steven Paulson, Barry Brooks, Ronald Kerr, Claude Denham, Michael Savin, Joanne Blum, Robert Kirby, Marvin Stone, John Pippen, Timothy George, Douglas Orr, Sally Knox, Michael Grant, George Peters, Daniel SavinoCharles Rietz

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

This prospective clinical trial was designed to assess the impact of adjuvant chemotherapy in women with rapidly proliferating node-negative breast cancer. This group has been predicted to have a 5-year disease-free survival (DFS) of 70% without adjuvant chemotherapy. In this study, 449 women with rapidly proliferating breast cancer (91% measured by S-phase fraction and 9% by histochemistry) received adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) plus tamoxifen for estrogen receptor-positive or progesterone receptor-positive cancer. The 5-year DFS was 90%

Original language	English (US)
Pages (from-to)	147-152
Number of pages	6
Journal	Clinical breast cancer
Volume	3
Issue number	2
DOIs	https://doi.org/10.3816/CBC.2002.n.019
State	Published - 2002

Keywords

Estrogen receptor
Progesterone receptor
Tamoxifen
Thymidine phosphorylase

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3816/CBC.2002.n.019

Cite this

Jones, S. E., Clark, G., Koleszar, S., Ethington, G., Mennel, R., Paulson, S., Brooks, B., Kerr, R., Denham, C., Savin, M., Blum, J., Kirby, R., Stone, M., Pippen, J., George, T., Orr, D., Knox, S., Grant, M., Peters, G., ... Rietz, C. (2002). Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer. Clinical breast cancer, 3(2), 147-152. https://doi.org/10.3816/CBC.2002.n.019

Jones, SE, Clark, G, Koleszar, S, Ethington, G, Mennel, R, Paulson, S, Brooks, B, Kerr, R, Denham, C, Savin, M, Blum, J, Kirby, R, Stone, M, Pippen, J, George, T, Orr, D, Knox, S, Grant, M, Peters, G, Savino, D & Rietz, C 2002, 'Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer', Clinical breast cancer, vol. 3, no. 2, pp. 147-152. https://doi.org/10.3816/CBC.2002.n.019

@article{50de8d6a21de4540abd03d2c50040d58,

title = "Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer",

abstract = "This prospective clinical trial was designed to assess the impact of adjuvant chemotherapy in women with rapidly proliferating node-negative breast cancer. This group has been predicted to have a 5-year disease-free survival (DFS) of 70% without adjuvant chemotherapy. In this study, 449 women with rapidly proliferating breast cancer (91% measured by S-phase fraction and 9% by histochemistry) received adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) plus tamoxifen for estrogen receptor-positive or progesterone receptor-positive cancer. The 5-year DFS was 90%",

keywords = "Estrogen receptor, Progesterone receptor, Tamoxifen, Thymidine phosphorylase",

author = "Jones, {Stephen E.} and Gary Clark and Sherry Koleszar and Gaby Ethington and Robert Mennel and Steven Paulson and Barry Brooks and Ronald Kerr and Claude Denham and Michael Savin and Joanne Blum and Robert Kirby and Marvin Stone and John Pippen and Timothy George and Douglas Orr and Sally Knox and Michael Grant and George Peters and Daniel Savino and Charles Rietz",

note = "Funding Information: Supported in part by a grant from the Wayne Endowment, Baylor Health Care System Foundation, Dallas, TX. Dr Clark{\textquoteright}s statistical assistance was supported in part by the National Cancer Institute Program Project Grant CA 30195.",

year = "2002",

doi = "10.3816/CBC.2002.n.019",

language = "English (US)",

volume = "3",

pages = "147--152",

journal = "Clinical breast cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

AU - Jones, Stephen E.

AU - Clark, Gary

AU - Koleszar, Sherry

AU - Ethington, Gaby

AU - Mennel, Robert

AU - Paulson, Steven

AU - Brooks, Barry

AU - Kerr, Ronald

AU - Denham, Claude

AU - Savin, Michael

AU - Blum, Joanne

AU - Kirby, Robert

AU - Stone, Marvin

AU - Pippen, John

AU - George, Timothy

AU - Orr, Douglas

AU - Knox, Sally

AU - Grant, Michael

AU - Peters, George

AU - Savino, Daniel

AU - Rietz, Charles

N1 - Funding Information: Supported in part by a grant from the Wayne Endowment, Baylor Health Care System Foundation, Dallas, TX. Dr Clark’s statistical assistance was supported in part by the National Cancer Institute Program Project Grant CA 30195.

PY - 2002

Y1 - 2002

N2 - This prospective clinical trial was designed to assess the impact of adjuvant chemotherapy in women with rapidly proliferating node-negative breast cancer. This group has been predicted to have a 5-year disease-free survival (DFS) of 70% without adjuvant chemotherapy. In this study, 449 women with rapidly proliferating breast cancer (91% measured by S-phase fraction and 9% by histochemistry) received adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) plus tamoxifen for estrogen receptor-positive or progesterone receptor-positive cancer. The 5-year DFS was 90%

AB - This prospective clinical trial was designed to assess the impact of adjuvant chemotherapy in women with rapidly proliferating node-negative breast cancer. This group has been predicted to have a 5-year disease-free survival (DFS) of 70% without adjuvant chemotherapy. In this study, 449 women with rapidly proliferating breast cancer (91% measured by S-phase fraction and 9% by histochemistry) received adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) plus tamoxifen for estrogen receptor-positive or progesterone receptor-positive cancer. The 5-year DFS was 90%

KW - Estrogen receptor

KW - Progesterone receptor

KW - Tamoxifen

KW - Thymidine phosphorylase

UR - http://www.scopus.com/inward/record.url?scp=0036348366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036348366&partnerID=8YFLogxK

U2 - 10.3816/CBC.2002.n.019

DO - 10.3816/CBC.2002.n.019

M3 - Article

C2 - 12123539

AN - SCOPUS:0036348366

SN - 1526-8209

VL - 3

SP - 147

EP - 152

JO - Clinical breast cancer

JF - Clinical breast cancer

IS - 2

ER -

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this